The impact of structural and functional parameters in glaucoma patients on patient-reported visual functioning

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Hirneiß, Christoph ^a   Reznicek, Lukas ^a   Vogel, Michaela ^a   Pesudovs, Konrad ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOMATED PERIMETER; CROSS-SECTIONAL STUDY; FEMALE; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTIC NERVE LESION; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PERIMETRY; QUESTIONNAIRE; RASCH CALIBRATED GLAUCOMA ACTIVITY LIMITATION 9 QUESTIONNAIRE; RETINAL NERVE FIBER LAYER THICKNESS; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISION; VISUAL ACUITY; VISUAL FIELD;

AGED; FEMALE; GLAUCOMA; HUMANS; MALE; MIDDLE AGED; SELF REPORT; TOMOGRAPHY, OPTICAL COHERENCE; VISION, OCULAR;

EID: 84891823336     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080757     Document Type: Article

References (49)

1. Quigley HA, Broman AT (2006) The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90: 262-267. doi: 10.1136/bjo.2005.081224. PubMed: 16488940.
2. Hood DC, Anderson SC, Wall M, Kardon RH (2007) Structure versus function in glaucoma: an application of a linear model. Invest Ophthalmol Vis Sci 48: 3662-3668. doi:10.1167/iovs.06-1401. PubMed: 17652736.
3. Hood DC, Kardon RH (2007) A framework for comparing structural and functional measures of glaucomatous damage. Prog Retin Eye Res 26: 688-710. doi:10.1016/j.preteyeres.2007.08.001. PubMed: 17889587.
4. Wollstein G, Kagemann L, Bilonick RA, Ishikawa H, Folio LS et al. (2012) Retinal nerve fibre layer and visual function loss in glaucoma: the tipping point. Br J Ophthalmol 96: 47-52. doi:10.1136/bjo. 2010.196907. PubMed: 21478200.
5. Schuman JS, Pedut-Kloizman T, Pakter H, Wang N, Guedes V et al. (2007) Optical coherence tomography and histologic measurements of nerve fiber layer thickness in normal and glaucomatous monkey eyes. Invest Ophthalmol Vis Sci 48: 3645-3654. doi:10.1167/iovs.06-0876. PubMed: 17652734.
6. Richman J, Lorenzana LL, Lankaranian D, Dugar J, Mayer J et al. (2010) Importance of visual acuity and contrast sensitivity in patients with glaucoma. Arch Ophthalmol 128: 1576-1582. doi:10.1001/archophthalmol.2010.275. PubMed: 21149782.
7. Mills RP, Janz NK, Wren PA, Guire KE (2001) Correlation of visual field with quality-of-life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). J Glaucoma 10: 192-198. doi: 10.1097/00061198- 200106000-00008. PubMed: 11442181.
8. Gutierrez P, Wilson MR, Johnson C, Gordon M, Cioffi GA et al. (1997) Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol 115: 777-784. doi:10.1001/archopht.1997.01100150779014. PubMed: 9194730.
9. Parrish RK 2nd, Gedde SJ, Scott IU, Feuer WJ, Schiffman JC et al. (1997) Visual function and quality of life among patients with glaucoma. Arch Ophthalmol 115: 1447-1455. doi:10.1001/archopht.1997.01100160617016. PubMed: 9366678.
10. Jampel HD, Frick KD, Janz NK, Wren PA, Musch DC et al. (2007) Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol 144: 238-244. doi:10.1016/j.ajo.2007.04.048. PubMed: 17560843.
11. Janz NK, Wren PA, Lichter PR, Musch DC, Gillespie BW et al. (2001) The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 108: 1954-1965. doi:10.1016/S0161-6420(01)00874-0. PubMed: 11713062.
12. McKean-Cowdin R, Wang Y, Wu J, Azen SP, Varma R (2007) Impact of Visual Field Loss on Health-Related Quality of Life in Glaucoma The Los Angeles Latino Eye Study. Ophthalmology 115: 941-948.e941
13. Aspinall PA, Johnson ZK, Azuara-Blanco A, Montarzino A, Brice R et al. (2008) Evaluation of quality of life and priorities of patients with glaucoma. Invest Ophthalmol Vis Sci 49: 1907-1915. doi:10.1167/iovs.07-0559. PubMed: 18436824.
14. Béchetoille A, Arnould B, Bron A, Baudouin C, Renard JP et al. (2008) Measurement of health-related quality of life with glaucoma: validation of the Glau-QoL 36-item questionnaire. Acta Ophthalmol Scand 86: 71-80. doi:10.1111/j.1600-0420.2007.00999.x. PubMed: 17725614.
15. Jampel HD, Schwartz A, Pollack I, Abrams D, Weiss H et al. (2002) Glaucoma patients' assessment of their visual function and quality of life. J Glaucoma 11: 154-163. doi: 10.1097/00061198-200204000-00012. PubMed: 11912364.
16. Kobelt G, Jonsson B, Bergström A, Chen E, Lindén C et al. (2006) Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand 84: 363-371. doi: 10.1111/j.1600-0420.2005.00621.x. PubMed: 16704699.
17. Lee BS, Kymes SM, Nease RF Jr., Sumner W, Siegfried CJ, et al. (2008) The impact of anchor point on utilities for 5 common ophthalmic diseases. Ophthalmology 115: 898-903 e894
18. Zanlonghi X, Arnould B, Bechetoille A, Baudouin C, Bron A, et al. (2003) [Glaucoma and quality of life]. J Fr Ophtalmol 26 Spec No 2: S39-44
19. Khadka J, Pesudovs K, McAlinden C, Vogel M, Kernt M et al. (2011) Re-engineering the Glaucoma Quality of Life-15 Questionnaire with Rasch. Analysis - Invest Ophthalmol Vis Sci 52: 6971-6977. doi: 10.1167/iovs.11-7423.
20. Nelson P, Aspinall P, Papasouliotis O, Worton B, O'Brien C (2003) Quality of life in glaucoma and its relationship with visual function. J Glaucoma 12: 139-150. doi:10.1097/00061198-200304000-00009. PubMed: 12671469.
21. Hirneiss C, Vogel M, Kampik A, Neubauer AS, Kernt M (2011) Measurement of glaucoma-specific functionality with the GQL-15 and correlation with parameters of visual function. Ophthalmologe 108: 939-946. doi:10.1007/s00347-011-2402-1. PubMed: 21779960.
22. Gothwal VK, Wright TA, Lamoureux EL, Pesudovs K (2009) Rasch analysis of the quality of life and vision function questionnaire. Optom Vis Sci 86: E836-E844. doi:10.1097/OPX.0b013e3181ae1ec7. PubMed: 19521266.
23. Severn P, Fraser S, Finch T, May C (2008) Which quality of life score is best for glaucoma patients and why? BMC Ophthalmol 8: 2. doi: 10.1186/1471-2415-8-2. PubMed: 18215284.
24. Spaeth G, Walt J, Keener J (2006) Evaluation of quality of life for patients with glaucoma. Am J Ophthalmol 141: S3-14. doi:10.1016/ j.ajo.2005.07.075. PubMed: 16389055.
25. Lundström M, Pesudovs K (2011) Questionnaires for measuring cataract surgery outcomes. J Cataract Refract Surg 37: 945-959. doi: 10.1016/j.jcrs.2011.03.010. PubMed: 21511158.
26. Marella M, Pesudovs K, Keeffe JE, O'Connor PM, Rees G et al. (2010) The psychometric validity of the NEI VFQ-25 for use in a low-vision population. Invest Ophthalmol Vis Sci 51: 2878-2884. doi:10.1167/iovs.09-4494. PubMed: 20089878.
27. Gothwal VK, Wright TA, Lamoureux EL, Pesudovs K (2010) Measuring outcomes of cataract surgery using the Visual Function Index-14. J Cataract Refract Surg 36: 1181-1188. doi:10.1016/j.jcrs.2010.01.029. PubMed: 20610098.
28. Savini G, Carbonelli M, Barboni P (2011) Spectral-domain optical coherence tomography for the diagnosis and follow-up of glaucoma. Curr Opin Ophthalmol 22: 115-123. doi:10.1097/ICU.0b013e3283437222. PubMed: 21307774.
29. Leite MT, Rao HL, Zangwill LM, Weinreb RN, Medeiros FA (2011) Comparison of the Diagnostic Accuracies of the Spectralis, Cirrus, and RTVue Optical Coherence Tomography Devices in Glaucoma. Ophthalmology 118: 1334-1339. PubMed: 21377735.
30. Seibold LK, Mandava N, Kahook MY (2010) Comparison of retinal nerve fiber layer thickness in normal eyes using time-domain and spectral-domain optical coherence tomography. Am J Ophthalmol 150: 807-814. doi:10.1016/j.ajo.2010.06. 024. PubMed: 20888550.
31. Hodapp E, Anderson DR (1993) Clinical decisions in glaucoma. St. Louis: Mosby.
32. Kymes S (2006) Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 142: 354; author reply: 355. doi:10.1016/j.ajo.2006.04.022. PubMed: 16876536.
33. Hurley SF, Matthews JP, Guymer RH (2008) Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc 6: 12. doi:10.1186/1478-7547-6-12. PubMed: 18573218.
34. Brown MM, Brown GC, Sharma S, Busbee B, Brown H (2001) Quality of life associated with unilateral and bilateral good vision. Ophthalmology 108: 643-648; discussion: 11297474.
35. Brown GC (2004) One eye versus two: a value-based approach. Curr Opin Ophthalmol 15: 165-166. doi:10.1097/01.icu. 0000120721.72077.b9. PubMed: 15118500.
36. Gothwal VK, Reddy SP, Bharani S, Bagga DK, Sumalini R et al. (2012) Impact of glaucoma on visual functioning in Indians. Invest Ophthalmol Vis Sci 53: 6081-6092. doi:10.1167/iovs.12-9885. PubMed: 22879424.
37. Kulkarni KM, Mayer JR, Lorenzana LL, Myers JS, Spaeth GL (2012) Visual field staging systems in glaucoma and the activities of daily living. Am J Ophthalmol 154: 445-451 e443
38. Altangerel U, Spaeth GL, Steinmann WC (2006) Assessment of function related to vision (AFREV). Ophthalmic Epidemiol 13: 67-80. doi:10.1080/ 09286580500428500. PubMed: 16510349.
39. Warrian KJ, Altangerel U, Spaeth GL (2010) Performance-based measures of visual function. Surv Ophthalmol 55: 146-161. doi: 10.1016/j.survophthal.2009. 06.006. PubMed: 20070999.
40. Warrian KJ, Lorenzana LL, Lankaranian D, Dugar J, Wizov SS, et al. (2010) The assessment of disability related to vision performance-based measure in diabetic retinopathy. Am J Ophthalmol 149: 852-860 e851
41. Finger RP, Fenwick E, Marella M, Dirani M, Holz FG et al. (2011) The impact of vision impairment on vision-specific quality of life in Germany. Invest Ophthalmol Vis Sci 52: 3613-3619. doi:10.1167/iovs.10-7127. PubMed: 21357395.
42. Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, et al. (2010) Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 117: 747-756 e744
43. Sumi I, Shirato S, Matsumoto S, Araie M (2003) The relationship between visual disability and visual field in patients with glaucoma. Ophthalmology 110: 332-339. doi:10.1016/S0161-6420(02)01742-6. PubMed: 12578777.
44. Lamoureux EL, Hassell JB, Keeffe JE (2004) The determinants of participation in activities of daily living in people with impaired vision. Am J Ophthalmol 137: 265-270. doi:10.1016/j.ajo.2003.08.003. PubMed: 14962415.
45. Ramulu P (2009) Glaucoma and disability: which tasks are affected, and at what stage of disease? Curr Opin Ophthalmol 20: 92-98. doi: 10.1097/ICU.0b013e32832401a9. PubMed: 19240541.
46. Lamoureux EL, Ferraro JG, Pallant JF, Pesudovs K, Rees G et al. (2007) Are standard instruments valid for the assessment of quality of life and symptoms in glaucoma? Optom Vis Sci 84: 789-796. doi: 10.1097/OPX. 0b013e3181334b83. PubMed: 17700342.
47. Pesudovs K (2010) Item banking: a generational change in patient-reported outcome measurement. Optom Vis Sci 87: 285-293. PubMed: 20142792.
48. Khadka J, McAlinden C, Craig JE, Fenwick EK, Lamoureux EL et al. (2013) Identifying Content for the Glaucoma-specific Item Bank to Measure Quality-of-life Parameters. J Glaucoma: ([MedlinePgn:]) PubMed: 23552836.
49. Chauhan BC, Burgoyne CF (2013) From clinical examination of the optic disc to clinical assessment of the optic nerve head: a paradigm change. Am J Ophthalmol 156: 218-227 e212